|Description||Alvimopan dihydrate is a novel, orally available peripherally restricted opioid antagonist with low systemic absorption. It accelerates the gastrointestinal recovery period with most common side effects in chronic pain patients with OBD were abdominal pai|
|Synonyms||2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid;dihydrate ADL 8-2698 ADL8-2698 alvimopan alvimopan anhydrous anhydrous alvimopan Entereg LY 246736 LY-246736 LY246736 trans-3,4-dimethyl-4-(3-hydroxyph|
|Storage||Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -75℃ for long term (months to years).|
|Shelf Life||2 years|
DAMGO is a highly selective peptide agonist of the μ opioid receptor.
(+)-U-50488 hydrochloride is the less active enantiomer of (±)-U-50488, which is an opioid receptor agonist.
Loperamide HCl is an opioid-receptor agonist with an ED50 of 0.15 mg/kg.
CTAP has been found to be a selective μ-opioid receptor antagonist.
DIPPA hydrochloride is an irreversible and selective antagonist of κ-opioid receptor (KOR).
Cebranopadol is a novel first-in-class compound with potent agonist activity on opioid receptor like-1(ORL-1) and the well established mu opioid receptor. It sh...
CHIR 4531, an oligopeptides compound, has been found to be an opioid mu receptor agonist and was once studied in pain therapy.
LY2795050, a κ-opioid Receptor antagonist, has been found to be effective in imaging KOR behaving as a PET tracer. IC50: 0.72 nM and 25.8 nM for κ-opioid Recept...